Physiological Pacing Reaches the High-Voltage Market: Biotronik Launches “Sky” ICD Series with LBBAP Integration
Key Highlights
- Biotronik officially launches the Acticor Sky and Rivacor Sky device families in CE-mark markets as of February 12, 2026.
- The series introduces the industry’s first ICD and CRT-D systems specifically approved for Left Bundle Branch Area Pacing (LBBAP).
- New MRI Guard 24/7 technology reduces the clinical burden of scanning VT patients, allowing for “always-on” sensor monitoring during imaging.
For the Global Ventricular Tachycardia (VT) Market, the challenge of “pacing-induced cardiomyopathy” has finally met a structural solution. For decades, traditional Implantable Cardioverter Defibrillators (ICDs) saved lives from sudden cardiac death but often weakened the heart over time by pacing from the right ventricle. Biotronik’s February 2026 launch of the Sky Series marks a fundamental shift toward Physiological Pacing in high-voltage therapy.
On February 12, 2026, Biotronik, a leader in cardiovascular CRM (Cardiac Rhythm Management), announced the commercial rollout of its Acticor Sky and Rivacor Sky device families. These devices represent a “next-generation” evolution for patients at risk of VT, particularly those with heart failure who require Cardiac Resynchronization Therapy (CRT-D).
The standout feature of the Sky series is its native support for LBBAP. Unlike traditional pacing, which forces an unnatural electrical wave through the heart muscle, LBBAP taps directly into the heart’s natural conduction system. This ensures that the ventricles contract in a synchronized, healthy rhythm. For VT patients, this is critical: maintaining a natural heart rhythm reduces the long-term strain on the heart, potentially lowering the frequency of life-threatening ventricular episodes that require painful shocks.
This launch is not merely a hardware update; it is a strategic repositioning in the CRM Market. While competitors have focused on leadless technology or smaller device footprints, Biotronik is doubling down on “Smart Pacing.” The Sky series includes the MRI Guard 24/7, which uses specialized sensors to automatically recognize an MRI environment and switch to a safe mode. In a market where VT patients frequently require MRI scans to map scar tissue, this automation eliminates the need for a technician to be present before and after every scan, significantly reducing hospital wait times.
The implications for the Ventricular Arrhythmia Supply Chain are profound. By integrating LBBAP directly into the device’s programming, Biotronik is forcing a “skills upgrade” across the industry. Electrophysiologists are shifting from simple lead placement to high-precision conduction system pacing. As of Q1 2026, this move has placed Biotronik at the forefront of the “Physiological Pacing” movement, a segment expected to grow at a CAGR of 12% over the next five years.
The outlook for the market is one of Holistic Care. The Sky series demonstrates that the future of VT management isn’t just about stopping a “VT Storm” when it happens, but about preserving the heart’s natural function to prevent the storm from forming in the first place. Biotronik has effectively raised the bar for what a “high-voltage” device should accomplish.
Strategic Market Intelligence
For deeper industry insights, explore MMR’s detailed market research reports: